Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

被引：0
|
作者：
Avram Goldberg
Thomas Geppert
Elena Schiopu
Tracy Frech
Vivien Hsu
Robert W Simms
Stanford L Peng
Yihong Yao
Nairouz Elgeioushi
Linda Chang
Bing Wang
Stephen Yoo
机构：
[1] Hofstra North Shore-LIJ School of Medicine,North Shore LIJ Health Systems and Division of Rheumatology
[2] Metroplex Clinical Research Center,undefined
[3] LLC,undefined
[4] University of Michigan,undefined
[5] University of Utah,undefined
[6] RWJ Medical School Clinical Research Center,undefined
[7] Boston University School Of Medicine,undefined
[8] Benaroya Research Institute at Virginia Mason Medical Center,undefined
[9] MedImmune,undefined
[10] MedImmune,undefined
来源：
Arthritis Research & Therapy | / 16卷
关键词：
Human Papilloma Virus; Chronic Myelogenous Leukemia; Evaluable Population; Positive Baseline; Minimum Anticipate Biological Effect Level;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
    Cohen, Fredric
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 87 - 94
  • [42] Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study
    Li, Qun
    Zhao, Wei
    Wang, Wei
    Chen, Po
    Niu, Zuoxing
    Ni, Shuqin
    Luo, Suxia
    Qiao, Junjing
    Wang, Mingxi
    Li, Yong
    He, Yan
    Liu, Tao
    Li, Tao
    Cai, Shengli
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in patients with relapsed or refractory solid tumours
    von Mehren, M.
    Britten, C.
    Piesolor, P.
    Balogh, K.
    Bartok, A.
    Harris, S.
    Li, X.
    Galluppi, J.
    Barton, J.
    Leong, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 128 - 128
  • [44] MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
    Hong, David S.
    Hui, David
    Bruera, Eduardo
    Janku, Filip
    Naing, Aung
    Falchook, Gerald S.
    Piha-Paul, Sarina
    Wheler, Jennifer J.
    Fu, Siqing
    Tsimberidou, Apostolia M.
    Stecher, Michael
    Mohanty, Prasant
    Simard, John
    Kurzrock, Razelle
    LANCET ONCOLOGY, 2014, 15 (06): : 656 - 666
  • [45] A phase 1 open-label, single-dose, dose-escalation study of Mdx-1100, a high-affinity, neutralizing, fully human Igg1κ anti-CXCL10 (Ip10) monoclonal antibody, in ulcerative colitis
    Hardi, Robert
    Mayer, Lloyd
    Targan, Stephan R.
    Yellin, Michael
    Cardarelli, Pina M.
    Das, Kiron M.
    GASTROENTEROLOGY, 2008, 134 (04) : A99 - A100
  • [46] A dose escalation, open-label, phase I/II study of AME-527, a novel anti-TNF monoclonal antibody (mAb) in subjects with active rheumatoid arthritis (RA)
    Tutuncu, ZN
    Boyle, D
    Lee, S
    Hallinan, J
    Weber, J
    Vasserot, A
    Breitmeyer, J
    Kavanaugh, A
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S346 - S346
  • [47] Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
    Taylor, Claribel P.
    Tummala, Sanjeev
    Molrine, Deborah
    Davidson, Lisa
    Farrell, Richard J.
    Lembo, Anthony
    Hibberd, Patricia L.
    Lowy, Israel
    Kelly, Ciaran P.
    VACCINE, 2008, 26 (27-28) : 3404 - 3409
  • [48] A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1)
    Winer, Ira Seth
    Patnaik, Amita
    Barve, Minal A.
    Kummar, Shivaani
    Schenk, Erin Lynn
    LoRusso, Patricia
    Yeku, Oladapo O.
    Fu, Siqing
    Jahchan, Nadine
    Myers, Matthew
    Liang, Linda
    Deegan, Denise
    Jackson, Lynnae
    Li, Yunfeng
    Reyno, Len
    Chamberlain, Marc Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] A Phase IIa Open-Label Dose-Escalation Pilot Study Using Allogeneic Human Dermal Fibroblasts for Nasolabial Folds
    Lowe, Nicholas J.
    Lowe, Philippa L.
    Roberts, John St Clair
    DERMATOLOGIC SURGERY, 2010, 36 (10) : 1578 - 1585
  • [50] MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Hofmeister, Craig C.
    Siegel, David
    Lonial, Sagar
    Zaki, Mohamad
    Hua, Ye
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth C.
    BLOOD, 2012, 120 (21)
12345